Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Silvia Varricchio
Institution:
University of Naples Federico II
Observed institution:
University of Naples Federico II
ORCID:
0000-0003-4984-0046
Observed ORCID:
0000-0003-4984-0046
OpenAlex ID:
A5123785094
Immunohistochemical and serum profile of squamous cell carcinoma of the vulva: The Dual Vulvar Panel (DVP) project
2026
·
Luigi Della Corte
, Mario Palumbo
, et al.
·
European Journal of Obstetrics & Gynecology and Reproductive Biology
·
2
PDF
Figure S1 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Supplementary Methods from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure 4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure 1 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Data from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure 2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure 3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Figure S5 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026
·
Daniela Criscuolo
, Francesco Merolla
, et al.
Show more works
View as search
Works count:
12
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type